Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Pharmaceuticals Regulatory News (HEMO)

Share Price Information for Hemogenyx Pharmaceuticals (HEMO)

Share Price is delayed by 15 minutes
Get Live Data
719.00    -5.00 (-0.69%)
Bid:
719.00
Ask:
745.00
Spread: 26.00 (3.616%)
Market Cap: £48.89m
HEMO Live PriceLast checked at - London Stock Exchange

Intraday Hemogenyx Pharmaceuticals Share Chart

Statement re possible acquisition

30 Dec 2015 07:00

RNS Number : 3726K
Silver Falcon PLC
30 December 2015
 

30 December 2015

SILVER FALCON PLC

("Silver Falcon" or the "Company")

 

Proposed acquisition of Lime Holdings Limited ("Lime")

 

Silver Falcon plc (LSE:SILF), the listed special purpose acquisition company, refers to its announcement of 23 December 2015 and is pleased to advise that it has entered into a non-binding Memorandum of Understanding with the board and principal shareholder in Lime Holdings Limited ("Lime") regarding a possible acquisition of 100% of the share capital of Lime by way of a share for share exchange ("Transaction").

Lime is an Australian unlisted public company which operates in the financial technology sector. It has developed an innovative platform for the insurance industry which facilitates the automated delivery of insurance to end users.

Lime has recently relocated its headquarters to the UK and is developing commercial partnerships in the UK and on an international basis.

Whilst a general understanding on the terms of the Transaction has been reached, these terms are subject to due diligence, a fundraising, and re-listing of the enlarged group on the London Stock Exchange. Accordingly there is no certainty that it will be completed.

If the Transaction is completed, it will constitute a reverse takeover under the Listing Rules. As the Company is unable to provide full disclosure under Rule 5.6.15 of the Listing Rules, the Company has requested a continuation of the current suspension of trading in its shares.

Further announcements will be made in due course as the Transaction progresses.

 

For further information please contact:

Silver Falcon: Tim Le Druillenec (Company Secretary), 07874 762821

Media enquiries: Jennifer Renwick, jennifer.renwick@camarco.co.uk, 0203 757 4994

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQTLBPTMBTTBAA
Date   Source Headline
27th Apr 20202:06 pmRNSSecond Price Monitoring Extn
27th Apr 20202:00 pmRNSPrice Monitoring Extension
22nd Apr 20204:40 pmRNSSecond Price Monitoring Extn
22nd Apr 20204:35 pmRNSPrice Monitoring Extension
22nd Apr 20202:05 pmRNSSecond Price Monitoring Extn
22nd Apr 20202:00 pmRNSPrice Monitoring Extension
22nd Apr 202011:00 amRNSCOVID-19 Project Initiated
21st Apr 20202:26 pmRNSApproval and Issuance of European Hu-PHEC Patent
2nd Apr 20202:05 pmRNSSecond Price Monitoring Extn
2nd Apr 20202:00 pmRNSPrice Monitoring Extension
28th Feb 20206:30 pmRNSTotal Voting Rights
20th Feb 20207:00 amRNSHEMO-CAR-T cells Effective Against AML in vivo
20th Feb 20207:00 amRNSHEMO-CAR-T cells Effective Against AML in vivo
11th Feb 20207:00 amRNSApproval and Issuance of U.S. Hu-PHEC Patent
31st Jan 20207:00 amRNSDirector/PDMR Shareholding
30th Jan 20202:05 pmRNSPlacing and Subscription to raise £650,000
15th Jan 202012:30 pmRNSHEMO's CAR-T Cells Effective Against AML in vitro
18th Nov 20197:00 amRNSOperational Update
12th Nov 20197:00 amRNSPresentation at the Investival Showcase
6th Nov 20197:00 amRNSPresentation at the NY Oncology Investor Conf.
23rd Oct 20197:00 amRNSResearch Agreement with Global Pharma Company
21st Oct 20197:00 amRNSPresentation at NY Stem Cell Foundation conference
30th Sep 20197:00 amRNSHalf-year Report
12th Sep 20197:00 amRNSHemogenyx scientific advisor receives Lasker Award
1st Aug 20197:00 amRNSTotal Voting Rights
12th Jul 20197:00 amRNSCDX Patent Application
3rd Jul 20197:00 amRNSDirector/PDMR Shareholding
28th Jun 201912:19 pmRNSResult of AGM
24th Jun 20197:00 amRNSDevelopment of ApbHC
12th Jun 20197:00 amRNSCDX Effective as Conditioning Therapeutic in vivo
5th Jun 20198:15 amRNSCDX Antibody is Effective against AML in vivo
30th May 20194:40 pmRNSSecond Price Monitoring Extn
30th May 20194:35 pmRNSPrice Monitoring Extension
30th May 20197:00 amRNSCDX Antibody is Effective against ALL in vitro
28th May 20197:00 amRNSPosting of Annual Report and Notice of AGM
15th May 20197:00 amRNSVariation of Terms of Warrant Instrument
1st May 20197:00 amRNSDirector/PDMR Shareholding
29th Apr 20193:10 pmRNSFinal Results for the Year Ended 31 December 2018
30th Jan 20197:00 amRNSPresentation at Cancer Immunotherapy Conference
7th Jan 20197:00 amRNSOperations Update
20th Dec 20187:00 amRNSDirectorate Change
5th Nov 20187:00 amRNSDirectorate Change & Appointment
22nd Oct 20187:00 amRNSOrgenesis collaboration for Hu-PHEC development
19th Oct 20187:00 amRNSCollaboration, License and Investment by Orgenesis
15th Oct 20187:00 amRNSCollaboration with Johnson & Johnson Innovation
28th Sep 20189:30 amRNSHalf-year Report
28th Sep 20187:00 amRNSChange of Adviser
3rd Sep 20187:00 amRNSHemogenyx to present at Oxford conference
27th Jun 201811:39 amRNSResult of AGM
8th Jun 20187:00 amRNSInvestor presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.